Clinical factors affecting serum potassium concentration in cardio-renal decompensation syndrome

International Journal of Cardiology

Volumn 138, Issue 2, 2010, Pages 174-181

  Ueno, Hirofumi ^a   Yoshimura, Michihiro ^b   Nakayama, Masafumi ^a   Yamamuro, Megumi ^a   Nishijima, Tsunenori ^a   Kusuhara, Kenichi ^a   Nagayoshi, Yasuhiro ^a   Kojima, Sunao ^a   Kaikita, Koichi ^a   Sumida, Hitoshi ^a   Sugiyama, Seigo ^a   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

B type natriuretic peptide; Heart failure; Potassium; RAAS inhibitors; Renal failure

Indexed keywords

ALACEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HEMOGLOBIN A1C; IMIDAPRIL; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; OLMESARTAN; PERINDOPRIL; POTASSIUM; QUINAPRIL; SPIRONOLACTONE; STEROID; TELMISARTAN; TEMOCAPRIL; THIAZIDE DIURETIC AGENT; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHILD; DISEASE PROGRESSION; DIURETICS; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; HYPERKALEMIA; KIDNEY FAILURE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; POTASSIUM; REGRESSION ANALYSIS; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; SPIRONOLACTONE; YOUNG ADULT;

EID: 73649138308     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.08.011     Document Type: Article

References (39)

1. Acker C.G., Johnson J.P., Palevsky P.M., and Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 158 8 (1998) 917-924
2. Bakris G.L., and Weir M.R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med 160 5 (2000) 685-693
3. Palmer B.F. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351 6 (2004) 585-592
4. Schepkens H., Vanholder R., Billiouw J.M., and Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 110 6 (2001) 438-441
5. Heywood J.T. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev 9 3 (2004) 195-201
6. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 23 (1987) 1429-1435
7. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 9386 (2003) 759-766
8. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 9335 (2002) 752-760
9. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 10 (1999) 709-717
10. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 14 (2003) 1309-1321
11. Perazella M.A. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 109 4 (2000) 307-314
12. Evans K.J. Greenberg A: hyperkalemia a review. J Intensive Care Med 20 5 (2005) 272-290
13. Textor S.C., Bravo E.L., and Fouad F.M. Tarazi RC Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 73 5 (1982) 719-725
14. Yoshimura M., Yasue H., Tanaka H., et al. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J 72 6 (1994) 528-533
15. Obialo C.I., Ofili E.O., and Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol 90 6 (2002) 663-665
16. Ahuja T.S., Freeman Jr. D., Mahnken J.D., Agraharkar M., Siddiqui M., and Memon A. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 20 4 (2000) 268-272
17. Reardon L.C., and Macpherson D.S. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?. Arch Intern Med 158 1 (1998) 26-32
18. Svensson M., Gustafsson F., Galatius S., Hildebrandt P.R., and Atar D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ 327 7424 (2003) 1141-1142
19. de Denus S., Tardif J.C., White M., et al. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. Am Heart J 152 4 (2006) 705-712
20. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 4 (1991) 1402-1412
21. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 1 (1994) 195-203
22. Imai E., Horio M., Nitta K., et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11 1 (2007) 41-50
23. Ljungman S., Laragh J.H., and Cody R.J. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 39 Suppl 4 (1990) 10-21 discussion 22-4
24. Novak L.P., and Harrison Jr. C.E. Abnormalities of cellular potassium concentration in uncompensated and compensated congestive heart failure. Mayo Clin Proc 48 2 (1973) 107-113
25. Jarman P.R., and Mather H.M. Diabetes may be independent risk factor for hyperkalaemia. BMJ 327 7418 (2003) 812
26. Jarman P.R., Kehely A.M., and Mather H.M. Hyperkalaemia in diabetes: prevalence and associations. Postgrad Med J 71 839 (1995) 551-552
27. Lewis E.J., Hunsicker L.G., Bain R.P., and Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 20 (1993) 1456-1462
28. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 12 (2001) 851-860
29. Winkelmayer W.C., Zhang Z., Shahinfar S., Cooper M.E., Avorn J., and Brenner B.M. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 29 10 (2006) 2210-2217
30. Yamamoto N., Yasue H., Mizuno Y., et al. Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 39 5 (2002) 958-962
31. Greenberg A. Diuretic complications. Am J Med Sci 319 1 (2000) 10-24
32. Zillich A.J., Garg J., Basu S., Bakris G.L., and Carter B.L. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48 2 (2006) 219-224
33. Macdonald J.E., and Struthers A.D. What is the optimal serum potassium level in cardiovascular patients?. J Am Coll Cardiol 43 2 (2004) 155-161
34. Bozkurt B., Agoston I., and Knowlton A.A. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 41 2 (2003) 211-214
35. Cruz C.S., Cruz A.A., and Marcilio de Souza C.A. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 18 9 (2003) 1814-1819
36. Wrenger E., Muller R., Moesenthin M., Welte T., Frolich J.C., and Neumann K.H. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 327 7407 (2003) 147-149
37. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334 15 (1996) 939-945
38. Robles N.R., Cancho B., Barroso S., Martin M.V., and Sanchez Casado E. Untoward effects of chronic dual renin-angiotensin system blockade: influence of previous chronic renal failure. Int J Clin Pract 60 9 (2006) 1035-1039
39. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150